Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InvestiGAIT: Bimagrumab Dose-Ranging in Older Adults With Sarcopenia
jRCT2080222848Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of bimagrumab in Sarcopenia (4 arms), sponsored by Novartis. Primary endpoints: Skeletal muscle strength and Physical function. Started May 2015; status: completed.
02
Drugs
bimagrumab
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on jRCT2080222848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222848.